Haematology

• 

  All Medical News

  ISH/BSH 2016: Professor Philippe Moreau from Nantes in France reviewed the rationale for the new diagnostic criteria and highlighted the gaps in current risk models for stratifying the risk of progression to MM… Also included article entitled ‘High-risk smouldering myeloma’

  Written by Lorraine Carolan | 2 Jun 2016

  High-risk smouldering myeloma by Maria Dalby Professor Philippe Moreau, University Hospital Hôtel-Dieu, Nantes, France Subsequent to the publication of updated diagnostic criteria for MM in 2014,1 MM clinicians have… read more.

• 

  All Medical News

  ISH/BSH 2016: Advances in our understanding of clonal evolution in MM: where are we now?

  Written by Lorraine Carolan | 2 Jun 2016

  Professor Keith Stewart, Mayo Clinic, Scottsdale, AZ, USA. by Maria Dalby: The dramatic improvement in MM survival in the last 40 years is largely linked to the introduction… read more.

• 

  All Medical News

  ISH/BSH 2016: Professor Keith Stewart (Mayo Clinic, USA) discusses his presentation from the presidential session on genomic sequencing in this video. Also included article entitled ‘Genome-guided therapy in multiple myeloma’

  Written by Lorraine Carolan | 1 Jun 2016

  Genome-guided therapy in multiple myeloma by Maria Dalby Professor Keith Stewart, Mayo Clinic, Scottsdale, AZ, USA Genomic sequencing of newly-diagnosed and refractory MM patients shows that combination therapy… read more.

• 

  All Medical News

  ISH/BSH 2016: Professor Graham Jackson (Newcastle-Upon-Tyne, UK) discusses the risk factors and patient characteristics that most inform treatment selection for patients with R/R MM. Also included article ‘Risk stratification in the older patient: what are our priorities?’

  Written by Lorraine Carolan | 31 May 2016

  Risk stratification in the older patient: what are our priorities? by Maria Dalby Professor Sonja Zweegman, VU University Medical Centre, Amsterdam, NL Biological age and frailty, rather than… read more.

• 

  All Medical News

  ISH/BSH 2016: Professor Graham Jackson (Newcastle-Upon-Tyne, UK) discusses the risk factors and patient characteristics that most inform treatment selection for patients with R/R MM. Also included article 'Risk stratification in the older patient: what are our priorities?'

  Written by Lorraine Carolan | 31 May 2016

  Risk stratification in the older patient: what are our priorities? by Maria Dalby Professor Sonja Zweegman, VU University Medical Centre, Amsterdam, NL Biological age and frailty, rather than… read more.

• 

  All Medical News

  ISH / BSH 2016: A well attended joint ISH / BSH meeting in Glasgow brought together cutting edge research from both the UK and international myeloma community, whilst allowing lively debate on how best to implement recent advances within the environment of the NHS. Professor Paul G. Richardson (Boston, USA) and Professor Graham Jackson (Newcastle-Upon-Tyne, UK) give an international and British perspective on highlights from the meeting.

  Written by Lorraine Carolan | 30 May 2016

• 

  All Medical News

  ISH / BSH 2016: Professor John Radford (The University of Manchester), Dr Graham Collins (Oxford University Hospitals) and Professor David Linch ( University College Hospital, London) give their highlights from this year’s BSH meeting in association with the 36th World Congress of the International Society of Hematology.

  Written by Lorraine Carolan | 30 May 2016

• 

  All Medical News

  Clot-buster lowers death risk in deadliest stroke

  Written by Bruce Sylvester | 1 Mar 2016

  by Bruce Sylvester: Tissue plasminogen activator (tPA) treatment with the clot-busting drug alteplase appears to be an effective way to decrease mortality in intraventricular hemorrhage, a catastrophic type… read more.

• 

  All Medical News

  ASH 2015: Building good combinations. Professor Sagar Lonial (Emory University School of Medicine, Atlanta, USA) discusses the benefits of building good combinations early on in therapy and the impact that newly available triplet oral therapy will have on patients with myeloma

  Written by Lorraine Carolan | 15 Feb 2016

• 

  All Medical News

  ASH 2015: Good news for patients from ASH! Erik Low (Chief Executive Myeloma UK), Professor Antonio Palumbo (University of Torino, Italy), Professor Paul Richardson (Harvard Medical School, Boston, USA) and Dr Shaji Kumar (Mayo Clinic, Rochester, USA) discuss the things they will take home to their myeloma patients folloing ASH 2015

  Written by Lorraine Carolan | 12 Feb 2016

• 

  All Medical News

  ASH 2015: Video Interview by Esther Drain. CDF changes affecting myeloma patients. Professor Graham Jackson (NCCC, Newcastle Hospitals Trust, UK) and Erik Low (Chief Executive Myeloma UK) discuss recent changes in the CDF and how they affect myeloma patients.

  Written by Lorraine Carolan | 11 Feb 2016

• 

  All Medical News

  ASH 2015: We ask Professor Sagar Lonial (Emory University School of Medicine, Atlanta, USA) what the role of PET/CT is as a measure of MRD post ASCT and ask Professor Antonio Palumbo (University of Torino, Italy) and Professor Graham Jackson (NCCC, Newcastle Hospitals Trust, UK) whether MRD measurement is ready for clinical use

  Written by Lorraine Carolan | 10 Feb 2016

  Role of minimal residual disease in treatment tailoring divides experts by Thomas R. Collins Minimal residual disease (MRD) is a guide for tailoring multiple myeloma whose time has… read more.